Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GX301 vaccination in castration-resistant prostate cancer
NCT02293707Phase 2Completed
- Sponsor
- Laboratoires Leurquin Mediolanum
- Start
- Nov 2014
- Primary completion
- Aug 2018
- Modality
- Peptide-based Cancer Vaccines
- Countries
- 2
01
Overview
Phase 2, randomised, open-label trial of GX301 in castration-resistant prostate cancer (CRPC) (3 arms), sponsored by Laboratoires Leurquin Mediolanum. Primary endpoints: Achievement of immunological response at Day 180, Incidence of adverse events at Day 180 and 1 more. Started Nov 2014; status: completed.
02
Drugs
GX301
03
Conditions
castration-resistant prostate cancer (CRPC)
Beyond the preview
Go deeper on NCT02293707.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02293707.